WASHINGTON, DC – CMS has implemented a new procedure to ensure DMEPOS supplier locations are open and available for an in-person inspection during this Public Health Emergency (PHE). Overland Solutions, a CMS subcontractor for the National Supplier Clearinghouse is currently completing these screenings by calling supplier locations.
The subcontractor has been instructed to indicate they are with Overland Solutions when contacting suppliers. Suppliers that received these screening calls have been asked questions about their current company address and if the supplier is operating from the location or from home.
Early in the PHE, CMS waived the requirement to be open at a physical location a minimum of 30 hours per week (supplier standard #7). However, in July 2020, CMS lifted this waiver and announced that they will be moving forward with physical inspections and assured that inspectors will follow state and local guidelines. You can find AAHomecare’s COVID-19 Medicare Reference Sheet for the list of active waivers during this PHE.
Second Quarter Revenue Up At ResMed
SAN DIEGO – In results for its quarter ended December 31, 2020, revenue at San Diego-based ResMed Inc. increased 9% to $800 million, up 7% on a constant currency basis. Net operating profit increased 12%.
“Our second-quarter results reflect continued solid performance and positive trends across our business resulting in top-line growth as well as double-digit improvement in operating income and earnings per share,” said Mick Farrell, ResMed CEO. “In our core markets of sleep apnea, COPD, and asthma, we are seeing continued sequential improvement in new patient volume and ongoing adoption of our mask and accessories resupply programs. Our global teams have managed SG&A investments judiciously as we navigate through the global pandemic. We have seen great adoption of digital health and an increase in the importance of out-of-hospital healthcare these last 12 months, and that will only expand throughout 2021 as vaccines become more widely available, and our communities open up worldwide. We have continued to invest in focused R&D programs in digital health and core medtech innovation, to help accelerate our ResMed growth strategy: improving 250 million lives in out-of-hospital healthcare in 2025.”